Live data · NADAC + Part D CY24 · reviewed daily

Efavirenz

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class · 5 generic manufacturers · 8 ANDAs filed at FDA.

First FDA approval2017-12-15
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$5.8M in CY2024 Part D spend16K claims · 3K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.28/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.30
Across all dosage forms in distribution.
Highest NADAC
$1.41
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Efavirenz used for?

Efavirenz is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Efavirenz?

Yes. 8 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Efavirenz?

Across 329 Part D plans, Efavirenz averages $1.30/unit (NADAC). Lowest available: $1.28/unit. Highest in distribution: $1.41/unit.

Is Efavirenz on the FDA shortage list?

No. Efavirenz is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.